#12355. Biomed Europa: After the coronavirus, a public infrastructure to overcome the pharmaceutical oligopoly

August 2026publication date
Proposal available till 31-05-2025
4 total number of authors per manuscript0 $

The title of the journal is available only for the authors who have already paid for
Journal’s subject area:
Sociology and Political Science;
Economics and Econometrics;
Places in the authors’ list:
place 1place 2place 3place 4
FreeFreeFreeFree
2350 $1200 $1050 $900 $
Contract №12355.1 Contract №12355.2 Contract №12355.3 Contract №12355.4
1 place - free (for sale)
2 place - free (for sale)
3 place - free (for sale)
4 place - free (for sale)

More details about the manuscript: Science Citation Index Expanded or/and Social Sciences Citation Index
Abstract:
After a brief analysis of the causes underlying the failure of both governments and the pharma industry in terms of preparedness for the COVID-19 pandemic and a discussion of further risks of health emergencies, this paper proposes a new public policy approach. The proposal aims at a major European initiative for the provision of research and development (R&D) in the biomedical field based on public health priorities. A plan is discussed for an international, interconnected, transparent, science-informed and publicly funded research infrastructure for pharmaceutical and biomedical research combined with a public enterprise: Biomed Europa. The proposed platform aims to identify research priorities in the public health sector, focusing its efforts on the development of preventive and therapeutic strategies against those diseases that will pose the greatest threats to human and social welfare over future decades.
Keywords:
biomedical research; COVID-19; pharmaceutical industry; public research infrastructure

Contacts :
0